Generex Oral-lyn: Phase III data

An open-label, Indian Phase III trial in 209 Type II diabetics inadequately controlled on oral anti-diabetic agents showed that Generex Oral-lyn significantly reduced HbA1c from baseline to week 6 vs. injected human insulin (0.48% vs. 0.05%, p<0.05). Generex Oral-lyn was non-inferior to injected human insulin in reducing HbA1c from baseline to week 12 (0.45% vs. 0.23%). Generex Oral-lyn was well tolerated. The trial was conducted by Shreya. ...